GlassScriptPhysician profile
Atif N Khan
NPI 1326303793
$1,257.35
in general payments reported to CMS, 2019-2025
19 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $165 · 2021: $285 · 2022: $211 · 2023: $364 · 2024: $37.28 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473 · Education: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.96 |
| Education | $122.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $172.59 | 2022-2025 | |
| Lilly USA, LLC | $150.41 | 2021-2023 | Jaypirca, Retevmo |
| Janssen Biotech, INC. | $124.54 | 2021-2025 | Rybrevant, Imbruvica, Tecvayli |
| Amgen INC. | $115.63 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $100.35 | 2021 | |
| Incyte Corporation | $91.79 | 2020-2022 | |
| Abbvie INC. | $84.22 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $60.80 | 2020-2023 | Keytruda, Welireg |
| Dendreon Pharmaceuticals LLC | $58.77 | 2022-2025 | Provenge |
| Jazz Pharmaceuticals INC. | $55.33 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.25 | 2021-2025 | Iclusig |
| Astellas Pharma US INC | $38.79 | 2022-2025 | Veozah |
| Genzyme Corporation | $35.37 | 2020-2021 | |
| Pfizer INC. | $28.66 | 2025 | |
| Deciphera Pharmaceuticals INC. | $22.22 | 2023 | Qinlock |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Institutional INC. | $21.50 | 2021 | |
| Array Biopharma INC | $19.49 | 2022 | |
| Caris Mpi, INC. | $19.29 | 2025 | Mi Cancer Seek |
| Bayer Healthcare Pharmaceuticals INC. | $14.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atif Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.